Latest News

Opsona News 3

Opsona receives orphan designation for MDS with OPN-305.

25th October 2016

Seroba’s investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug and development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it has received orphan drug designation (ODD) from United States […]

Read More
Veryan Premarket Approval

Veryan Completes enrolment into the MIMICS-2 clinical study

24th October 2016

The MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of BioMimics 3D in the treatment of patients with symptomatic femoropopliteal disease. The Study is being conducted under a USA Food and Drug Administration […]

Read More
Quanta News

Quanta presents interim analysis of first 255 treatments using SC+

20th September 2016

Seroba’s investee company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announced that it will present a poster at a moderated session on Friday 23rd […]

Read More
Veryan Premarket Approval

Veryan announces first patient enrolment into MIMICS-3D Registry

15th September 2016

MIMICS-3D is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Self-Expanding Stent System in the treatment of peripheral arterial disease. The Registry will evaluate safety, effectiveness and device performance within a real-world clinical population in a minimum of […]

Read More
Veryan News

Veryan Medical Announces Trial Results

13th June 2016

Veryan Medical has announced the achievement of four significant milestones in its MIMICS clinical programme: (1) The publication of the Mimics Study article; (2) The enrolment of the 200th patient in the MIMICS-2 IDE Study; (3) The first live case […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top